Imunon (NASDAQ:IMNN – Get Free Report) posted its quarterly earnings data on Tuesday. Institutional Trading of ImunonA hedge fund recently raised its stake in Imunon stock. DRW Securities LLC increased its stake in Imunon, Inc. (NASDAQ:IMNN – Free Report) by 6.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. Imunon Company Profile(Get Free Report)Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. Recommended StoriesReceive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.